Pfizer and Lily have developed a new treatment medication, called a PK 4/6 inhibitor, that provides dramatic benefits for women with hormone sensitive breast cancer.
Prolonged longevity and reduced death rate are seen with the well-tolerated medication, with additional testing pending to provide the final proof that the treatment should become widely used and widely available.
Read more>>>>>>HERE.